C-Reactive Protein and Risk of Lung Cancer
- 1 June 2010
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 28 (16), 2719-2726
- https://doi.org/10.1200/jco.2009.27.0454
Abstract
Purpose Chronic inflammation could play a role in lung carcinogenesis, underscoring the potential for lung cancer prevention and screening. We investigated the association of circulating high-sensitivity C-reactive protein (CRP, an inflammation biomarker) and CRP single nucleotide polymorphisms (SNPs) with prospective lung cancer risk. Patients and Methods We conducted a nested case-control study of 592 lung cancer patients and 670 controls with available prediagnostic serum and 378 patients and 447 controls with DNA within the screening arm of the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (N = 77,464). Controls were matched to patients on age, sex, entry year, follow-up time, and smoking. We measured CRP levels in baseline serum samples and genotyped five common CRP SNPs. Results Elevated CRP levels were associated with increased lung cancer risk (odds ratio [OR], 1.98; 95% CI, 1.35 to 2.89; P-trend < .001 for fourth quartile [Q4, ≥ 5.6 mg/L] v Q1 [< 1.0 mg/L]). The CRP association did not differ significantly by histology, follow-up time, or smoking status, but was most apparent for squamous cell carcinomas (OR, 2.92; 95% CI, 1.30 to 6.54), 2 to 5 years before lung cancer diagnosis (OR, 2.33; 95% CI, 1.24 to 4.39), and among former smokers (OR, 2.48; 95% CI, 1.53 to 4.03) and current smokers (OR, 1.90; 95% CI, 1.06 to 3.41). Although CRP SNPs and haplotypes were associated with CRP levels, they were not associated with lung cancer risk. Ten-year standardized absolute risks of lung cancer were higher with elevated CRP levels among former smokers (Q4: 2.55%; 95% CI, 1.98% to 3.27% v Q1: 1.39%; 95% CI, 1.07% to 1.81%) and current smokers (Q4: 7.37%; 95% CI, 5.81% to 9.33% v Q1: 4.03%; 95% CI, 3.01% to 5.40%). Conclusion Elevated CRP levels are associated with subsequently increased lung cancer risk, suggesting an etiologic role for chronic pulmonary inflammation in lung carcinogenesis.This publication has 38 references indexed in Scilit:
- Inflammation in the development of lung cancer: epidemiological evidenceExpert Review of Anticancer Therapy, 2008
- Impact of cancers and cardiovascular diseases in chronic obstructive pulmonary diseaseCurrent Opinion in Pulmonary Medicine, 2008
- Impaired lung function and lung cancer incidence in a cohort of Swedish construction workersThorax, 2007
- State of the Art. Chronic Obstructive Pulmonary Disease, Inflammation, and Lung CancerProceedings of the American Thoracic Society, 2006
- Plasma C-Reactive Protein and Risk of Cancer: A Prospective Study from GreeceCancer Epidemiology, Biomarkers & Prevention, 2006
- Circulating Levels of Inflammatory Markers and Cancer Risk in the Health Aging and Body Composition CohortCancer Epidemiology, Biomarkers & Prevention, 2005
- Epidemiology of Lung Cancer: Looking to the FutureJournal of Clinical Oncology, 2005
- The Potential Contributions of Chronic Inflammation to Lung CarcinogenesisClinical Lung Cancer, 2003
- A meta-analysis of asthma and risk of lung cancer (United States)Cancer Causes & Control, 2003
- BUTYLATED HYDROXYTOLUENE (BHT) INDUCTION OF PULMONARY INFLAMMATION: A Role in Tumor PromotionExperimental Lung Research, 2001